AU2018326364B2 - Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease - Google Patents

Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease Download PDF

Info

Publication number
AU2018326364B2
AU2018326364B2 AU2018326364A AU2018326364A AU2018326364B2 AU 2018326364 B2 AU2018326364 B2 AU 2018326364B2 AU 2018326364 A AU2018326364 A AU 2018326364A AU 2018326364 A AU2018326364 A AU 2018326364A AU 2018326364 B2 AU2018326364 B2 AU 2018326364B2
Authority
AU
Australia
Prior art keywords
migalastat
patient
salt
mwfs
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018326364A
Other languages
English (en)
Other versions
AU2018326364A1 (en
Inventor
Jay Barth
Jeff Castelli
Nina SKUBAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amicus Therapeutics Inc
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63528948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018326364(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of AU2018326364A1 publication Critical patent/AU2018326364A1/en
Application granted granted Critical
Publication of AU2018326364B2 publication Critical patent/AU2018326364B2/en
Priority to AU2024266945A priority Critical patent/AU2024266945A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2018326364A 2017-08-28 2018-08-28 Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease Active AU2018326364B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024266945A AU2024266945A1 (en) 2017-08-28 2024-11-27 Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762550984P 2017-08-28 2017-08-28
US62/550,984 2017-08-28
PCT/US2018/048257 WO2019046244A1 (en) 2017-08-28 2018-08-28 METHODS FOR ENHANCING AND / OR STABILIZING CARDIAC FUNCTION IN PATIENTS WITH FABRY DISEASE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024266945A Division AU2024266945A1 (en) 2017-08-28 2024-11-27 Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease

Publications (2)

Publication Number Publication Date
AU2018326364A1 AU2018326364A1 (en) 2020-04-09
AU2018326364B2 true AU2018326364B2 (en) 2024-08-29

Family

ID=63528948

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018326364A Active AU2018326364B2 (en) 2017-08-28 2018-08-28 Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease
AU2024266945A Pending AU2024266945A1 (en) 2017-08-28 2024-11-27 Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024266945A Pending AU2024266945A1 (en) 2017-08-28 2024-11-27 Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease

Country Status (26)

Country Link
US (1) US20200222377A1 (enExample)
EP (3) EP3675853B1 (enExample)
JP (3) JP7755929B2 (enExample)
KR (2) KR102790184B1 (enExample)
CN (1) CN111770753A (enExample)
AR (1) AR112482A1 (enExample)
AU (2) AU2018326364B2 (enExample)
CA (1) CA3074450C (enExample)
CL (1) CL2020000491A1 (enExample)
DK (2) DK4176877T3 (enExample)
EA (1) EA202090564A1 (enExample)
ES (2) ES2931054T3 (enExample)
FI (1) FI4176877T3 (enExample)
HR (2) HRP20250064T1 (enExample)
HU (2) HUE070433T2 (enExample)
IL (3) IL272893B2 (enExample)
LT (2) LT4176877T (enExample)
MX (2) MX2020002229A (enExample)
PL (2) PL4176877T3 (enExample)
PT (2) PT4176877T (enExample)
RS (2) RS66515B1 (enExample)
SG (1) SG11202001707PA (enExample)
SI (1) SI4176877T1 (enExample)
SM (2) SMT202500073T1 (enExample)
TW (1) TWI845479B (enExample)
WO (1) WO2019046244A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX351004B (es) 2006-05-16 2017-09-26 Nat Institutes Of Health Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
AU2018277756A1 (en) 2017-05-30 2020-01-23 Amicus Therapeutics, Inc. Methods of treating fabry patients having renal impairment
WO2019046244A1 (en) 2017-08-28 2019-03-07 Amicus Therapeutics, Inc. METHODS FOR ENHANCING AND / OR STABILIZING CARDIAC FUNCTION IN PATIENTS WITH FABRY DISEASE
EP4717319A3 (en) 2018-02-06 2026-06-10 Amicus Therapeutics, Inc. Methods of treating fabry disease in pregnant patients
LT3840753T (lt) 2018-08-20 2024-11-11 Amicus Therapeutics, Inc. Migalastatas skirtas naudoti fabry ligos gydymo būdui, pacientams turintiems gla geno mutaciją
KR20220044560A (ko) * 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
TR2024011149A1 (tr) 2024-08-23 2026-03-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Mi̇galastat i̇çeren kapsül formülasyonlari
CN119120696A (zh) * 2024-11-12 2024-12-13 北京贝瑞和康生物技术有限公司 检测法布雷病gla基因突变的引物组、试剂盒及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
EP2142197A4 (en) 2007-03-30 2010-11-10 Amicus Therapeutics Inc METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES
US9999618B2 (en) * 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
WO2019046244A1 (en) 2017-08-28 2019-03-07 Amicus Therapeutics, Inc. METHODS FOR ENHANCING AND / OR STABILIZING CARDIAC FUNCTION IN PATIENTS WITH FABRY DISEASE
US10811814B2 (en) 2017-08-28 2020-10-20 John Mezzalingua Associates, LLC Weather protecting (WP) housing for coaxial cable connectors

Also Published As

Publication number Publication date
IL272893B2 (en) 2024-07-01
CN111770753A (zh) 2020-10-13
HUE060287T2 (hu) 2023-02-28
SG11202001707PA (en) 2020-03-30
HUE070433T2 (hu) 2025-06-28
FI4176877T3 (fi) 2025-03-06
PT3675853T (pt) 2022-11-28
PL4176877T3 (pl) 2025-04-07
EP4176877B1 (en) 2024-12-04
CL2020000491A1 (es) 2020-09-11
EP4176877A1 (en) 2023-05-10
CA3074450C (en) 2024-10-01
DK3675853T3 (da) 2022-11-28
IL310648A (en) 2024-04-01
WO2019046244A1 (en) 2019-03-07
EP3675853B1 (en) 2022-09-07
RS63742B1 (sr) 2022-12-30
SMT202200459T1 (it) 2023-01-13
RS66515B1 (sr) 2025-03-31
JP7755929B2 (ja) 2025-10-17
BR112020003974A2 (pt) 2020-09-01
IL272893B1 (en) 2024-03-01
EP4588476A1 (en) 2025-07-23
IL324182A (en) 2025-12-01
EA202090564A1 (ru) 2020-06-15
KR20200044908A (ko) 2020-04-29
TW201919619A (zh) 2019-06-01
DK4176877T3 (da) 2025-02-24
IL272893A (en) 2020-04-30
SI4176877T1 (sl) 2025-03-31
CA3074450A1 (en) 2019-03-07
TWI845479B (zh) 2024-06-21
KR20250049561A (ko) 2025-04-11
KR102790184B1 (ko) 2025-04-01
HRP20221366T1 (hr) 2023-01-06
PL3675853T3 (pl) 2022-12-27
EP3675853A1 (en) 2020-07-08
HRP20250064T1 (hr) 2025-03-14
PT4176877T (pt) 2025-02-24
JP2020531550A (ja) 2020-11-05
MX2023005628A (es) 2023-05-24
SMT202500073T1 (it) 2025-03-12
US20200222377A1 (en) 2020-07-16
ES3013820T3 (en) 2025-04-15
LT4176877T (lt) 2025-02-10
MX2020002229A (es) 2020-07-20
AU2024266945A1 (en) 2024-12-19
JP2025138638A (ja) 2025-09-25
AU2018326364A1 (en) 2020-04-09
LT3675853T (lt) 2022-12-12
JP2023051998A (ja) 2023-04-11
AR112482A1 (es) 2019-10-30
ES2931054T3 (es) 2022-12-23

Similar Documents

Publication Publication Date Title
AU2024266945A1 (en) Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease
JP7784398B2 (ja) Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法
KR102631805B1 (ko) 신장 손상을 갖는 파브리 환자를 치료하는 방법
AU2025217396A1 (en) Treatment of fabry disease in ert-naïve and ert-experienced patients
AU2025200074A1 (en) Treatment of patients with classic fabry disease
JP2025131572A (ja) 腎機能障害を有する患者のファブリー病を治療する方法
AU2024278298A1 (en) Use of migalastat for treating fabry disease in pregnant patients
JP2026082813A (ja) ファブリー病の治療方法
CN114159436A (zh) 治疗在gla基因中具有g9331a突变的患者的法布里病的方法
JP2025128105A (ja) ファブリー病患者の脳血管事象のリスク低減におけるミガロスタットの使用
JP2026016375A (ja) Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法
CN111278438A (zh) 治疗具有肾损害的法布里患者的方法
HK40039916A (en) Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease
HK40085360A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40044440A (en) Treatment of patients with classic fabry disease
HK40031708A (en) Methods of treating fabry patients having renal impairment
HK40001720A (en) Methods of treating fabry disease in patients having the g9331a mutation in the gla gene

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)